Rivoceranib
- Generic Name
- Rivoceranib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 145
- Registration Number
- NCT05759572
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Drug: Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 258
- Registration Number
- NCT05751733
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: TACEDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05717738
- Locations
- 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: HAICDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ze-yang Ding, MD
- Target Recruit Count
- 300
- Registration Number
- NCT05713994
- Locations
- 🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳TongjiHospital, Wuhan, Hubei, China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Conditions
- Immunotherapy Gastrict Cancer
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05699655
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Advanced or Metastatic Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2022-12-16
- Target Recruit Count
- 60
- Registration Number
- NCT05653817
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Conditions
- ImmunotherapyPreoperativeHepatocellular Carcinoma
- Interventions
- Procedure: Radical surgeryProcedure: Preoperative TACE treatment
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-31
- Target Recruit Count
- 130
- Registration Number
- NCT05613478
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05597527
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast CancerBreast NeoplasmBreast CancerHormone Receptor Positive Tumor
- Interventions
- Drug: AKT inhibitorDrug: CarrelizumabDrug: SHR-1167Drug: TPCDrug: SHR-6209
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Breast NeoplasmHER2-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorBreast CancerBreast TumorsHormone Receptor Negative TumorTriple-Negative Breast Cancer (TNBC)Locally Advanced Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.